Created with Sketch.
GeekWire Health Tech
49 minutes | Oct 19, 2021
Inside Seattle's life sciences boom
Five years ago, when Dr. Leslie Alexandre arrived in Seattle to lead the industry group Life Science Washington, she found a community in a mild state of shock. "One of the real challenges was our ecosystem had tons of great research going on, and many wonderful companies, but I think our industry was a little bit in the doldrums in 2016, in part because Amgen had just completed moving out of Elliott Bay," she said. "It started in 2014. And when I arrived, it was just the last people." Amgen was the giant that five years earlier acquired Seattle’s homegrown biotech standout Immunex, known for developing the Enbrel arthritis drug, still widely prescribed to this day. Immunex was based on a big waterfront campus, which today is home to Expedia Group’s global headquarters. But there had been hopes in the local community that Amgen would maintain and even expand its operations in the region after the Immunex acquisition. "And having it move away was kind of, 'Oh my gosh, one more company, one more great company created here in Seattle, breathtaking research commercialization. And now it's gone," Alexandre said. But that’s just the beginning of the story. On this episode of the GeekWire Health Tech Podcast, what happened next, and where the Seattle region’s life sciences industry stands today. Our guest, Leslie Alexandre is the President and CEO at life science, Washington, an organization that aims to put Washington state at the forefront of global life science innovation, who recently announced her plans to retire at the end of the year. The organization is holding its annual Washington State Life Science Summit virtually this week, Thursday Oct. 21. Dr. Alexandre received her Doctorate of Public Health from UCLA and has held leadership roles at startups, Fortune 500 companies, research institutions and non-profit organizations. She ran the North Carolina Biotechnology Center from 2002-2007. Episode produced and edited by GeekWire co-founder Todd Bishop, with reporting and research by Charlotte Schubert, GeekWire health and life sciences reporter, who also joins us on this episode.See omnystudio.com/listener for privacy information.
33 minutes | Aug 4, 2021
Testing Amazon's COVID Test
Amazon made headlines at the height of the pandemic for developing its own COVID-19 testing system for its workers. The same test is now available to the public for $40. You can order the test on Amazon.com, take it at home and ship it to Amazon to get your results. So what is it like to take Amazon’s COVID test? We decided to find out. On this episode, GeekWire reporter Charlotte Schubert goes hands-on with Amazon’s COVID-19 test, adding to our understanding of the tech giant’s emerging health initiatives. We also hear from an expert in the field, Jerry Cangelosi, a University of Washington professor who has studied the effectiveness of these types of self-administered COVID-19 tests. Read more in this GeekWire story. Thanks to the sponsor of Health Tech Season 5, Premera Blue Cross.See omnystudio.com/listener for privacy information.
31 minutes | Jun 24, 2021
What it's like to use Amazon Pharmacy
Amazon's move into healthcare is multifaceted, including COVID-19 testing, its Halo health band and service, cloud services for healthcare and life sciences, and even primary care for its employees. A major motivation for the company: the sheer size of the healthcare market, and the massive problems to be solved. "Amazon is a big company now, still with big growth ambitions, and so they need to tackle big markets," said John Rossman, a former Amazon business leader and the author of The Amazon Way, speaking on a recent episode of GeekWire's Day 2 podcast. "Healthcare is going to become a bigger and bigger component of what their strategy is going to be, from every angle." But one of the tech giant's healthcare initiatives seems especially well-positioned to benefit from Amazon's traditional e-commerce expertise: prescriptions by mail. The company launched its Amazon Pharmacy service in November 2020, building on its 2018 acquisition of prescription-by-mail company PillPack. "Really, we wanted to make a pharmacy experience that was just as easy to use as Amazon generally," said TJ Parker, the PillPack CEO and vice president in charge of Amazon Pharmacy, and a former practicing pharmacist himself. Amazon is competing against traditional pharmacies such as CVS, Walgreens and RiteAid, big retail rivals such as Walmart and Target, and healthcare technology companies such as GoodRx — whose chief financial officer, Karsten Voermann, sought to downplay the competitive threat from Amazon on a recent earnings call. "Based on third-party data, they have not been successful," Voermann said of Amazon. "Mail order prescriptions only make up about 5% of fill count in the U.S. ... Third-party data indicates that Amazon Pharmacy is not gaining momentum and that their volume remains incredibly small." But this is Amazon, a company with the resources and tenacity to pursue big challenges and opportunities for many years. So what's it like to use Amazon Pharmacy? To find out, GeekWire's Todd Bishop signed up to test the service on a routine prescription refill. Amazon Pharmacy impressed him with its convenience and privacy. But he also encountered obstacles, some due to kinks in the healthcare system outside of Amazon's control, that made the overall experience less than seamless. On this episode of GeekWire's Health Tech Podcast, Todd talks with Amazon's TJ Parker to learn more about the Amazon Pharmacy, using his experience to inform the discussion.See omnystudio.com/listener for privacy information.
22 minutes | May 12, 2021
Son's rare disease inspires dad to disrupt drug development
Before their son was born, Sanath Kumar Ramesh and his wife Ramya had normal first-time-parent jitters. Ramesh, who works for Amazon as a software engineering manager, was so excited to welcome his little boy. He was ready for the challenges and rewards of parenthood. In August 2018, Raghav was born, and Ramesh’s life began changing in ways he’d never expected. On this episode of GeekWire's Health Tech Podcast, we’re reconnecting with Ramesh to hear more of his compelling, inspiring story. We previously reported on Ramesh and Raghav’s doctors and their efforts to treat Raghav. In this podcast we go deeper into Ramesh’s experience as both a father and a talented tech engineer working to help both his son and others struggling to save loved ones battling rare diseases.See omnystudio.com/listener for privacy information.
27 minutes | Mar 31, 2021
How AI will accelerate the response to the next pandemic
The speed of the creation of vaccines for the SARS-CoV-2 virus that causes COVID-19 was a modern marvel. You might already have already gotten yours. But what if vaccines and therapeutics could emerge even faster in response to the next pandemic. That’s one of the goals of a $5 million gift from Microsoft to the Institute for Protein Design at the University of Washington School of Medicine. On this episode, we talk with Microsoft’s chief scientific officer, Eric Horvitz, and the director of the UW institute, David Baker, about the new age of artificial intelligence and biotechnology, and the potential to engineer a very different future.See omnystudio.com/listener for privacy information.
34 minutes | Mar 9, 2021
Walter Isaacson on the gene editing revolution
Walter Isaacson has studied and written extensively about the physics and technology revolutions as the biographer of such figures as Albert Einstein and Steve Jobs. But after writing his latest book, he is convinced there's a far more momentous revolution in the works. "The next few decades are going to be the era of biotech," he said in a GeekWire podcast conversation about his new book, The Code Breaker: Jennifer Doudna, Gene Editing and the Future of the Human Race. "We'll be able to do totally amazing things that will not only make us healthier but in some ways will transform our species. So as much as I love the digital revolution, I think this is the big one." The book explores the history and implications of gene editing through the stories of scientists and other key figures in the field. The central character is Jennifer Doudna, the UC Berkeley biochemist who won the Nobel Prize for Chemistry in 2020 with French geneticist Emmanuelle Charpentier for their discoveries and work in CRISPR gene editing. Isaacson is a professor of history at Tulane who was previously CEO of The Aspen Institute, chair of CNN and editor of Time. See omnystudio.com/listener for privacy information.
25 minutes | Mar 4, 2021
Finding secrets of life in close brushes with death
To help people live, Mark Roth scrutinizes those who've come frighteningly close to dying. People who have been lost in the frozen wilderness in a Mount Rainier whiteout or stowed away in the wheel well of a trans-Pacific jet. People who have suffered massive heart attacks or body-crushing car wrecks. Roth, a biochemist and cell biologist at Seattle's Fred Hutchinson Cancer Research Center, sees a thread connecting these catastrophes with something seemingly quite different: immortality. Both conditions "press pause" on life, he said. It's playing dead without being dead. An entrepreneur and past winner of a MacArthur "Genius Grant," Roth built a career on making unlikely, unconventional, scientific connections. He shares the story of his extraordinary work on this episode of GeekWire’s Health Tech Podcast, reported and hosted by GeekWire reporter Lisa Stiffler.See omnystudio.com/listener for privacy information.
34 minutes | Feb 26, 2021
Testing a new COVID-19 test
GeekWire editor Todd Bishop: On a cold, clear weekday morning last month, my quest to figure out whether I had COVID-19 in the early days of the pandemic took me to my back porch, where a mobile phlebotomist drew my blood. It had been 10 months since I was sick, and I had already received a negative result on a standard antibody test. That earlier test was designed to detect the presence of the antibodies produced by the body’s immune system to ward off the virus that causes COVID-19. The negative result meant I probably didn't have COVID back in March. But given the possibility of a false negative in the antibody test, I wasn’t giving up that easily. And this test was different. This was a first-of-its kind diagnostic tool from Seattle-based Adaptive Biotechnologies, a company that develops technology to sequence the human immune system for the diagnosis and treatment of disease. T-cells are specialized cells that determine the human immune system’s response to disease. Adaptive says tell-tale signs of T-cell responses to specific diseases can be detected earlier and longer than antibody responses, and with a higher degree of accuracy. Adaptive Biotechnologies’ new test, called T-Detect COVID, was developed in partnership with Microsoft officially launched this week, under CLIA Clinical Laboratory Improvement Amendments federal regulations. The Food and Drug Administration is reviewing the T-Detect COVID test for Emergency Use Authorization (EUA). The test costs $150 plus lab fees. On this episode of the GeekWire Health Tech Podcast, we’ll talk with Lance Baldo, Adaptive's chief medical officer, to learn exactly how this test works, and what it could mean for diagnosing and treating a wide range of diseases. And yes, I’ll finally learn almost definitely, whether I had COVID or not. See omnystudio.com/listener for privacy information.
20 minutes | Feb 11, 2021
'Data saves lives': U.S. health systems unite behind new startup
A group of 14 U.S. health systems, representing tens of millions of patients across 40 states, will pool data using software developed by Seattle startup Truveta, leveraging artificial intelligence to search for medical breakthroughs and previously undetected patterns of inequity in healthcare. The company, led by former Microsoft Windows chief Terry Myerson, gave new details about its origins and plans Thursday morning, saying it has grown to 53 employees. Truveta emerged from stealth mode in October. Created and governed by the participating health systems, Truveta says its goal is to extract insights from large amounts of health data, using those insights to improve healthcare without sacrificing the privacy of patients. The health systems will use software developed by Truveta to remove personally identifying information from the data. In addition, the company says it will be able to provide researchers with statistically representative populations for studies and clinical trials. Appearing on this episode are Myerson, the Truveta CEO; and Dr. Rod Hochman, president and CEO of Providence, the Renton, Wash.-based health system where the initiative began.See omnystudio.com/listener for privacy information.
31 minutes | Jan 21, 2021
Halo Effect: Amazon, privacy, and the future of health
GeekWire editor Todd Bishop: A few weeks ago, I started wearing a new health band. It regularly eavesdrops on my side of conversations, and it has a lot of opinions about them. “You had three phrases that sounded annoyed, irritated or disgusted," a section in the app reported on a recent evening, recapping my daily interactions. Not only that, but I had "one phrase that sounded stubborn or condescending.” Another feature invites me to strip down to my underwear for a picture. "Find a well-lit area and try to avoid light from behind," a voice from the app instructed me as it prepared to conduct a high-tech, 3D body scan. "Change into minimal clothing so the camera can see your body.” Yes, as you might have guessed by now, this is the Amazon Halo band and subscription service, part of the tech giant’s big move into health and wellness. Thanks to its revelations, I am now painfully aware of my tone of voice, and more empathetic toward my family and friends who have to put up with me. I've informed the Amazon team of a feature request from my wife, who would like to receive an emailed report on my tone of voice at the end of each day. As for the body scan, let's just say this is one image that I won't be publishing with this story, and you're welcome. You might have seen reviews of Halo. The Washington Post’s Geoffrey A. Fowler and Heather Kelly wrote that it “collects the most intimate information we’ve seen from a consumer health gadget — and makes the absolute least use of it.” Based on my own experience, I agree with the first point, but not the second. Yes, Halo pushes the limits of my comfort zone at times. I have yet to get the motivation to take a second body scan after the first experience. But I have also started to rely on several of the features, including the in-depth sleep analysis and the tone assessment — two big areas where I personally have lots of room for improvement. The band is comfortable to wear, and the programs in the app are useful. Just this week I boosted my time in deep sleep after doing a recommended progressive muscle relaxation exercise available in the Halo app before bed. And despite concerns from U.S. Sen. Amy Klobuchar and others about the personal data Halo collects, I've found Amazon to be transparent about what it's doing, and clear in enabling me as the user to choose to participate, or not, in the more invasive aspects of the app. Yet Amazon could be doing even more to build trust. On this episode of the GeekWire Health Tech Podcast, we explore the future of health — and test the limits of personal privacy — through Amazon’s new health band and service. We talk with the principal medical officer on the Amazon Halo team to get the inside details on what the company is doing, and we hear an outside assessment of Amazon’s privacy and security promises from an independent expert. Episode edited and produced by Josh Kerns of Cypress Point Strategic Communications.See omnystudio.com/listener for privacy information.
31 minutes | Dec 29, 2020
COVID-19: After the vaccine
To say that Dr. Brad Younggren has a unique perspective on COVID-19 would be an understatement -- because he actually has multiple perspectives. Dr. Younggren is the chief medical officer at Seattle-based healthcare startup 98point6, which has seen interest in its on-demand virtual care service skyrocket amid the pandemic. He's also an emergency physician, and the medical director for emergency preparedness, at EvergreenHealth Medical Center, in Kirkland, Wash., the first hospital in the country to manage an influx of COVID-19 patients earlier this year. And he has been on the front lines before, literally, as a former U.S. Army physician who earned a Bronze Star and the Combat Medic Badge for his service in Iraq. So it was with a sense of hope and cautious optimism that he received his first dose of COVID-19 vaccine last week, along with his Evergreen colleagues. "It's been an intense year, working through this massive growth at 98point6, and seeing how we can support the country at scale," he said. "Then the individual work, taking care of patients at Evergreen, has definitely been tasking at times. It's been an emotional experience just to see the light at the end of the tunnel — that sense of hope that comes from interval change in how we're managing this pandemic." With cases surging in the U.S., Younggren and his colleagues are careful to note that we're not out of the woods yet. But even when the world can put the pandemic into the history books, COVID-19's impact on the science and technology of healthcare will endure. He drew parallels between his time serving in the military and the past year in the pandemic, in terms of its impact on people working in healthcare. There's a "battle rhythm you develop, because you're basically on all the time, and there's a level of fatigue that comes from that kind of work," he said. "We're seeing a lot written about the impact of COVID-19 on the healthcare worker, and not just the physicians, the nurses and the janitors and the people who are cleaning the rooms. It's impacting the entire healthcare system. These are very stressful times from that perspective." Younggren reflects on the past year, and talks about what's next, on this episode of GeekWire's Health Tech Podcast. See omnystudio.com/listener for privacy information.
32 minutes | Dec 10, 2020
Wait, was that COVID?!
Did you get really sick in the first few months of the year? Do you wonder if it was COVID-19? You're not alone. On the Season 5 premiere of the GeekWire Health Tech Podcast, we revisit the early days of the pandemic in an effort to figure out a mysterious illness, with help from experts at the University of Washington, Fred Hutchinson Cancer Research Center and ZoomCare. We come away with a deeper understanding of the nuances of COVID-19 testing, and insights into how the outbreak is changing the detection and treatment of disease. Hosted and produced by GeekWire editor Todd Bishop, with guests Dr. Erik Vanderlip, ZoomCare chief medical officer, and Dr. Alex Greninger, an Assistant Professor in the Department of Laboratory Medicine and Pathology at the University of Washington Medical Center. Season 5 of the GeekWire Health Tech Podcast is sponsored by Premera Blue Cross.See omnystudio.com/listener for privacy information.
21 minutes | Jun 15, 2020
Inside the boom in remote patient monitoring
The last time we caught up with Pillsy co-founders Jeff LeBrun and Chuks Onwuneme, three years ago, they were focused on their flagship product, a smart pill bottle that sounds an alarm if people forget to take their pills. But that was just one example of the broader trend of remote patient monitoring -- technology that helps medical professionals keep tabs on the status of patients at home, day in and day out, not just during periodic visits to the doctor’s office. Even before COVID-19 led to a boom in telehealth, LeBrun says, the need for better remote patient monitoring was becoming clear to Medicare officials, due to an aging population and a limited supply of health care workers. "There's been over a decade of research showing that remote patient monitoring has led to improved health outcomes and reduced costs," LeBrun says. "With a system that's already stretched thin, they knew that they needed to use more technology to try to handle this coming load of care that they would need to provide over the next 10 years. And so I think we're really just at the tip of the iceberg. Certainly what we're seeing now is accelerating that approach."See omnystudio.com/listener for privacy information.
2 minutes | May 19, 2020
Webinar with Fred Hutch president - Special Invite
GeekWire Health Tech Podcast subscriber, you're invited to join us at 1:30 p.m. Pacific this Thursday, May 21, for a live online discussion with Dr. Thomas Lynch, the new president of the Fred Hutchinson Cancer Research Center. You may have caught my earlier conversation with Dr. Lynch on this podcast when he was just starting in the job, back in February. Of course, a lot has happened since then! Register for the webinar here. Scientists from the Seattle-based institute have emerged as leaders in the global effort to understand, track and reduce the spread of COVID-19. We’ll talk with Dr. Lynch about those initiatives, as well as Fred Hutch’s core cancer research efforts, and get an update on his long-term vision for Fred Hutch as an institution. Participation in these live webinars is normally exclusive to GeekWire members, but as a health tech podcast subscriber, you’re invited to join us for this one as our guest, and sample one of the perks of membership to see if you’d like to join. Go here to register and submit a question, and join us online this Thursday See omnystudio.com/listener for privacy information.
25 minutes | May 15, 2020
The quest for a better COVID-19 test
In the world of diagnostic tests for COVID-19, there are two main approaches: PCR tests, which detect the presence of the live virus; and serology tests, which detect antibodies that indicate whether someone has recovered from the disease. But could there be a third way? Two companies based in the Seattle region, Microsoft and Adaptive Biotechnologies, are working together to try to create a better diagnostic test. Joining us to explain the initiative are Peter Lee, Microsoft corporate vice president of AI and Research, and Adaptive CEO Chad Robins. At a basic level, Microsoft and Adaptive are looking for the unique signature associated with COVID-19 in the specialized cells that determine the human immune system's response to the disease. Once that signature is identified, they say, it could lead to a new test that would detect the tell-tale signs of the disease in others, providing a new form of diagnosis. The companies last week launched a virtual clinical study, seeking 1,000 people across the country who have been diagnosed with, exposed to, or recovered from COVID-19. The study is called “ImmuneRACE,” for Immune Response Action to COVID-19 Events. It focuses on 20 major metro regions in the US.. As of earlier this week, the study had more than 100 participants out of the 1,000 it’s seeking.See omnystudio.com/listener for privacy information.
31 minutes | Apr 30, 2020
Psychedelics and the Future of Health
We’re exploring the intersection of psychedelics, health care, mental health and even spirituality with a journalist who has been reporting on the topic for GeekWire, two entrepreneurs looking to capitalize on future legalization of psychedelics, and a physician scientist who uses a form of psychedelics as part of his practice of medicine and psychotherapy. Related stories COVID-19 mental health crunch puts impetus on psychedelic drug innovation, doctor says Oregon psychedelic startup tests nasal spray for PTSD, depression as legislative momentum builds With Oregon activists pushing for state-wide decriminalization of magic mushrooms for therapeutic use this year, one local startup wants to keep the momentum going. Silo Wellness, based in Springfield, Oregon, has developed a nasal spray for microdosing psilocybin meant to aid with anxiety, PTSD and depression. The company now hopes to spread the good word, offering seminars for volunteers who normally wouldn't try it on the black market to test the device in a controlled setting in Jamaica, where magic mushrooms are legal. Joining us for this discussion Mike Arnold, founder of Silo Wellness; entrepreneur and consultant Eric Boone of Cannabinovation.com; Dr. Sunil Aggarwal, an affiliate clinical assistant professor at the University of Washington School of Medicine; and journalist Anastasia Ustinova. As the deadly coronavirus pandemic continues to grow, the looming mental health crisis creates an urgent need for innovation, putting a spotlight on psychedelic-assisted treatments, says Aggarwal, the co-founder of Advanced Integrative Medical Science Institute (AIMS) in Seattle.See omnystudio.com/listener for privacy information.
22 minutes | Apr 15, 2020
An Objective Test for Autism?
SPOKANE, Wash. — If you showed up at an emergency room with a heart attack, you’d expect to receive some diagnostic tests like pulse, blood pressure and an EKG. You’d be surprised if medical professionals based their assessment only on how you looked, or how they perceived your behavior that day. Yet, that is exactly how autism spectrum disorder is diagnosed. Dr. Georgina Lynch, an assistant professor at Washington State University in Spokane, Wash., says autism is assessed with too limited a set of tools, focusing only on sociability and behavior markers that can often be perceived subjectively by healthcare providers. She started Appiture Biotechnologies to bring a new objective autism test to the healthcare market. Researchers have long hoped that a genetic marker or blood test would offer an objective clue to diagnosing autism. Instead, Dr. Lynch’s approach is based on what she finds to be a unique reaction to light in the pupils of people on the autism spectrum. “When we think of autism as just a behavioral or mental health disorder, that's the first mistake,” she said. “We need to think about it as a biological condition.” Read more and see a video of the test at geekwire.com/healthtech. This week's episode was reported, hosted and produced for GeekWire by Meredith Hogan, an independent multimedia journalist who produces documentary podcasts, video, films and interactive features. She worked previously for NBCNews.com and has a BS in Journalism from Northwestern University. Follow her @mer_hogan.See omnystudio.com/listener for privacy information.
35 minutes | Apr 7, 2020
COVID-19 and the future of health tech
Much of the current focus in health care is rightly on the near-term challenges of the COVID-19 pandemic. But beyond the current crisis, health care technology veterans are already seeing major changes that promise to become permanent realities -- from the sudden boom in telemedicine, to regulatory shifts impacting health care billing, to the use of location data to track the disease. "Most interesting is what's going to happen when this is over," says Anne Weiler, the co-founder and former CEO of Seattle health tech startup Wellpepper, recently acquired by Caravan Health. "I don't think people are going to be satisfied with going back to the status quo, because these other things are now working." "I think these regulatory changes represent a big shift in how health care will be delivered beyond 2020," adds Nirav Shah, CEO of Sentinel Healthcare, a neurologist and the former stroke director at Swedish Hospital in Seattle. Sentinel recently launched a real-time fever tracking app for COVID-19 cases, and today announced that UT Health Austin will roll out its quarantine management program. But it will be key to deliver solutions that actually work for front-line health care workers, says Doug Cusick, CEO of Seattle startup TransformativeMed, which is offering its electronic record keeping application to screen COVID-19 patients, monitor symptom checklists, and track lab results and other data. "Look to technology to solve problems, but don't forget about these poor clinicians who've been left out in the process," Cusick explains. "The view has to be into solving these big communication and collaboration problems, which will enable so much else to work across our ecosystem." We introduced these health tech leaders recently and brought them together for a conversation about the COVID-19 crisis. The conversation quickly turned to the long-term implications for hospitals, clinicians, startups, patients and health technology. As a bonus, here are some of Anne Weiler's recommended Twitter accounts to follow, which she alluded to during the show. @ScottGottliebMD @RanaAwdish @meganranney @leorahorwitzmd @DrSidMukherjee @UrbaneDoc4Kids @Farzad_MD @ShawnteJamesMD See omnystudio.com/listener for privacy information.
14 minutes | Mar 26, 2020
The Quest for Masks
On this episode: FindTheMasks.com,GetUsPPE.org and Masks 4 WA. The coronavirus outbreak in Washington state has not yet reached the "peak" some public health officials anticipate but already ICU physicians like Mike Holmes are grappling with a dearth of necessary supplies. Holmes described an "extreme shortage" of masks he and his colleagues at Swedish Medical Center in Seattle need to treat COVID-19 patients. "We are now reusing single-use masks over and over and over again," he said. It's a challenge facing healthcare workers across Washington, who are asking the general public to donate any personal protective equipment (PPE) they have. Though Washington is receiving some supplies from the federal stockpile of protective equipment, people on the front lines of the crisis say it is not enough. But long before Washington became a hotspot for COVID-19, it was an epicenter of innovation, home to Microsoft, Amazon, Boeing, and hundreds of tech startups known for creative problem-solving. Many of those innovators are now stepping up to find ways around supply chain challenges and the global shortage of protective gear for healthcare providers. GeekWire's Monica Nickelsburg joins us with the story on this special episode of the GeekWire Health Tech Podcast. See omnystudio.com/listener for privacy information.
12 minutes | Mar 16, 2020
AI vs. Coronavirus
A consortium of tech leaders — including Seattle’s Allen Institute for Artificial Intelligence and Microsoft — today unveiled an AI-enabled database that’s meant to give researchers quicker, surer access to resources relating to coronavirus and how to stop it. GeekWire science editor Alan Boyle explains the initiative on this special episode of the GeekWire Health Tech Podcast. Read his story here.See omnystudio.com/listener for privacy information.
Terms of Service
Do Not Sell My Personal Information
© Stitcher 2021